相关实验视频

Updated: Sep 13, 2025

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Receptor Autoradiography Protocol for the Localized Visualization of Angiotensin II Receptors

Published on: June 7, 2016

氨基酶对 ангиотензин和它们的作用血压作用

Peter Forster^1,2, Jan Wysocki¹, Yasemin Abedini¹

¹Division of Nephrology and Hypertension, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

International journal of molecular sciences

|July 29, 2025

概括

氨基酶A (APA) 快速降解Ang II,表明对高血压的治疗潜力. 此外,APA还通过Ang II依赖和独立的途径代谢益高血压Ang-(1-12).

科学领域:

生物化学和分子生物学
心血管生理学心血管生理学
酶学是一种酶学.

背景情况:

氨基酶A (APA) 是一种酶,可以从中分离N端的酸残留物.
胺-血管素系统 (RAS) 在血压调节中起着至关重要的作用.
一些RAS,包括Ang II,具有N端亚斯巴酸盐,是APA的基质.

研究的目的:

研究重组APA (r-APA) 对各种RAS的水解作用,包括Ang-(1-12).
要确定Ang-(1-12) 是否通过Ang II形成或独立的机制来发挥其压力作用.
评估r-APA和遗传APA缺陷对Ang-(1-12) 的压力活性的影响.

主要方法:

开发一种测试方法,通过r-APA测量Ang I,Ang II,Ang-{1-7},Ang-{1-9}和Ang-{1-12}的裂变.
与或没有ACE抑制剂 (利西诺普利尔) 或AT1受体阻断剂 (特尔米萨坦) 的Ang-(1-12) 给药,以评估压力反应.
在r-APA或r-ACE2的存在下输注Ang I,Ang II和Ang-(1-12),以评估它们对血压的影响.

主要成果:

r-APA有效地将N端的阿斯巴达酸盐从Ang II,Ang-(1-12),Ang I,Ang-(1-9和Ang-(1-7中分离出来.
利西诺普里尔或特尔米沙坦可以消除Ang-(1-12) 的压力活性,这表明它在Ang II形成中发挥了作用.
r-APA可以减弱Ang-I和Ang-II的压力效应,但不能减轻Ang-{1-12}的压力效应,这表明Ang-{1-12}的压力机制是独立于Ang-{1-12}的.

结论:

通过快速降解Ang II,APA表现出抗高血压作用,突出了其在Ang II依赖高血压的治疗潜力.
二甲1-12) 具有由二甲形成和二甲独立途径介导的抗高血压作用.
APA代谢Ang-(1-12),通过AngII依赖和独立的机制影响其抗高血压作用.

关键词:

氨基酸酶A 是一种氨基酸酶.血管新生素是一种 ангиотензин II 的使用血管素- ((1-12)) 的使用.氨酸 ангиотензин系统的氨酸.

更多相关视频

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Nitropeptide Profiling and Identification Illustrated by Angiotensin II

Published on: June 16, 2019

相关概念视频

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Angiotensin II Receptor Blockers

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antihypertensive Drugs: Action of β1 Blockers

Antihypertensive Drugs: Action of β₁ Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...

Hormonal Regulation

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.